The influence of hydrophilic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (pravastatin) on gelatinase activity in vitro

Pharmaceutical Biology

Volumn 47, Issue 10, 2009, Pages 924-926

  Kurzepa, Jacek ^a   Stryjecka Zimmer, Marta ^a   Szczepaska Szerej, Anna ^a   Kurzepa, Joanna ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Gelatinase; MMP 2; MMP 9; Pravastatin

Indexed keywords

GELATIN; GELATINASE A; GELATINASE B; HETERODIMER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PRAVASTATIN;

ADULT; ARTICLE; BLOOD SAMPLING; DRUG EFFECT; ELECTROPHORESIS; ENZYMATIC DEGRADATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; IN VITRO STUDY; INCUBATION TIME; MALE; MOLECULAR WEIGHT; NEUTROPHIL; NORMAL HUMAN; PROTEIN EXPRESSION; ZYMOGRAPHY;

EID: 77149169471     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.1080/13880200902942451     Document Type: Article

References (12)

1. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, Meyer J, Cambien F, Tiret L, Atherogene investigators (2003): Plasma concentrations and genetic variation of matrix metal-loproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107:1579-1585.
2. Castillo J, Rodriguez I (2004): Biochemical changes and inflammatory response as markers for brain ischemia: Molecular markers of diagnostic utility and prognosis in human clinical practice. Cerebrovasc Dis 17: S7-18.
3. De Angelis G (2004): The influence of statin characteristics on their safety and tolerability. Int J Clin Vrac 58: 945-955.
4. Hartung HP, Kieseier BC (2000): The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J Neuroimmunol 107: 140-147.
5. Kieseier BC, Archelos JJ, Hartung HP (2004): Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases. Arch Neurol 61: 929-932.
6. Kurzepa J, Stryjecka-Zimmer M (2007): The effect of interferon beta-la on MMP-2 and MMP-9 proteolytic activity. Folia Biol (Praha) 53:220-221.
7. Laws PE, Spark JI, Cowled PA, Fitridge RA (2004): The role of statins in vascular disease. Eur J Vasc Endovasc Surg 27: 6-16.
8. Matuu TS, Royle L, Langridge J (2000): O-Glycan analysis of natural human neutrophil gelatinase B using a combination of normal phase-HPLC and online tandem mass spectrometry: Implications for the domain organisation of the enzyme. Biochemistry 39: 15696-15704.
9. Neuhaus O, Strasser-Fuchs S, Fazekas F, Kieseier BC, Niederwieser G, Hartung HP, Archelos JJ (2002): Statins as immunomodulators: Comparison with interferon-beta lb in MS. Neurology 59: 990-997.
10. Opdenakker G, Van den Steen PE, Van Damme J (2001): Gelatinase B: A tuner and amplifier of immune functions. Trends Immunol 22: 571-579.
11. Polette M, Nawrocki-Raby B, Gilles C, Clavel C, Birembaut P (2004): Tumor invasion and matrix metalloproteinases. Clinical Rev Oncol/Hematol 49: 179-186.
12. Snoek-van Beurden PA, Von den Hoff JW (2005): Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors. Biotechniques 38: 73-83.